DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Somatuline Depot (Lanreotide Acetate) - Published Studies

 
 



Published Studies Related to Somatuline Depot (Lanreotide)

Well-designed clinical trials related to Somatuline Depot (Lanreotide)

Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. [2010.04]

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. [2010]

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. [2010]

Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae. [2009.12]

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. [2009.11]

Lanreotide Reduces the Volume of Polycystic Liver: A Randomized, Double-Blind, Placebo-Controlled Trial. [2009.07.29]

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. [2009.02.03]

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. [2006.11.15]

Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial. [2006.05]

Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. [2005.11]

Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. [2005.07]

Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion. [2004.01]

The role of lanreotide in the treatment of choroidal neovascularization secondary to age-related macular degeneration: a pilot clinical trial. [2003.12]

Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis. [2003.10.15]

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. [2003.07.15]

Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study. [2002.02]

Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. [2002.01]

Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. [2001.10]

Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. [2000.11]

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. [2000.02.15]

Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers. [1999.04]

Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study. [1998.04]

Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. [1997.01]

Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. [1994.03]

Well-designed clinical trials possibly related to Somatuline Depot (Lanreotide)

Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. [2011.08]

Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. [2010.06]

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. [2010.06]

Relative bioavailability of two drug products of somatropin obtained from either the milk of transgenic cows or bacterial culture. [2010]

Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. [2008.06]

Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. [2004.03]

A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. [2004.02]

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. [2004.01]

Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues. [2001.12]

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. [2000.12]

Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment. [2000.09]

The use of long-acting somatostatin analogues in acromegaly. [2000.04]

Effect of long-acting somatostatin analog (Somatulin) on renal hyperfiltration in patients with IDDM. [1997.04]

Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men. [1992.12]

[Influence of dose and modalities of administration of BIM 23014 on growth hormone secretion in patients with acromegaly] [1992]

Other research related to Somatuline Depot (Lanreotide)

Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. [2013]

The long-term outcome of patients with polycystic liver disease treated with lanreotide. [2012]

The long-term outcome of patients with polycystic liver disease treated with lanreotide. [2011.11.24]

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. [2011.08.24]

Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). [2011.08]

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. [2011.03]

Efficacy and acceptability of lanreotide Autogel(R) 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. [2011.03]

Pharmacokinetic evaluation of lanreotide. [2010.10]

Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats. [2010.09]

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. [2010.06]

Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. [2010.05]

Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats. [2010.04]

A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide. [2010.03]

Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. [2010.02]

Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. [2010.01.05]

Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. [2010]

Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. [2009.08]

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel((R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. [2009.07.29]

Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. [2009.06]

Lanreotide for the treatment of acromegaly. [2009.06]

Efficacy of long-term lanreotide treatment in patients with acromegaly. [2009.03.06]

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. [2009.03]

Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC). [2009.02]

Population pharmacokinetic analysis of lanreotide autogel((r)) in healthy subjects : evidence for injection interval of up to 2 months. [2009]

Long-acting lanreotide in adolescent girls with constitutional tall stature. [2009]

Efficacy of long-term lanreotide treatment in patients with acromegaly. [2009]

Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. [2008.11]

Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. [2008.10]

The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. [2008.08.05]

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. [2008.08]

Lanreotide Autogel for persistent diabetic macular edema. [2008.06]

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. [2008.06]

A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. [2008.03]

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. [2008.01.31]

Raltegravir. [2008]

Spotlight on lanreotide Autogel in acromegaly. [2008]

Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. [2007.12]

Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. [2007.12]

Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. [2007.11]

Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. [2007.10]

Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation. [2007.05.07]

Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. [2006.09]

Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. [2004.04]

Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy. [2001.09]

GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. [2001.04]

Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. [2001]

Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. [2000.08]

Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications. [2000.06]

Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. [2000.06]

A comparison of lanreotide and octreotide LAR for treatment of acromegaly. [1999.09]

Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. [1997.01]

Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. [1995.11]

Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology. [1995.06]

Other possibly related research studies

Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. [2008.04]

Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs. [2008.05]

Consensus statement of the Polish Society for Endocrinology: presurgical somatostatin analogs therapy in acromegaly. [2008.02]

[Consensus of the Polish Society of Endocrinology. Presurgical somatostatin analogs therapy in acromegaly] [2007.07]

Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. [2007.05]

Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. [2006]

Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. [2006.06]

Treatment of pituitary tumors: somatostatin. [2005.10]

Current pharmacotherapy for acromegaly: a review. [2005.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017